FIELD: biotechnology.
SUBSTANCE: invention relates to an antibody molecule that specifically binds to CTLA-4, as well as to a pharmaceutical composition containing it. Also a nucleic acid encoding the above molecule, as well as a plasmid, a virus, and a cell containing it are disclosed.
EFFECT: invention is effective for the treatment of cancer.
33 cl, 41 dwg, 8 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DELIVERY OF THERAPEUTIC POLYPEPTIDES VIA PSEUDOTYPED ONCOLYTIC VIRUSES | 2017 |
|
RU2758007C2 |
| ONCOLYTIC HERPES SIMPLEX VIRUSES TYPE 1 FOR TREATING BRAIN TUMOURS | 2021 |
|
RU2824514C1 |
| KIR3DL3 INHIBITORY RECEPTOR OF IMMUNE SYSTEM AND USE THEREOF | 2020 |
|
RU2827900C1 |
| ONCOLYTIC HSV-VECTOR | 2014 |
|
RU2719190C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| ANTIBODIES BINDING CTLA-4 AND APPLICATION THEREOF | 2018 |
|
RU2756100C1 |
| PD-1 BINDING ANTIBODIES AND METHODS OF THEIR USE | 2019 |
|
RU2812280C1 |
| ANTIBODIES BINDING TO PD-1 AND THEIR APPLICATIONS | 2019 |
|
RU2773758C2 |
| CD30XCD16 ANTIBODY COMBINATION FOR THERAPY WITH PD-1 ANTAGONIST | 2016 |
|
RU2761352C2 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
